CY1122765T1 - Ξηρανθεισα με ψεκασμο συνθεση αc220 - Google Patents

Ξηρανθεισα με ψεκασμο συνθεση αc220

Info

Publication number
CY1122765T1
CY1122765T1 CY20201100138T CY201100138T CY1122765T1 CY 1122765 T1 CY1122765 T1 CY 1122765T1 CY 20201100138 T CY20201100138 T CY 20201100138T CY 201100138 T CY201100138 T CY 201100138T CY 1122765 T1 CY1122765 T1 CY 1122765T1
Authority
CY
Cyprus
Prior art keywords
dosage
composition
spray dried
methods
benzothiazol
Prior art date
Application number
CY20201100138T
Other languages
English (en)
Inventor
Robert E. Corringham
Patrick B. O'donnell
Joyce K. James
Original Assignee
Ambit Biosciences Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambit Biosciences Corporation filed Critical Ambit Biosciences Corporation
Publication of CY1122765T1 publication Critical patent/CY1122765T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Vaporization, Distillation, Condensation, Sublimation, And Cold Traps (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Παρέχονται εδώ μέθοδοι χορήγησης N-(5-τριτ-βουτυλο-ισοξαζολ-3-υλ)-Ν'-{4-[7- (2-μορφολιν-4-υλ-εθοξυ)ιμιδαζο[2,1-b][1,3]βενζοθειαζολ-2-υλ]φαινυλο}ουρίας, ή ενός φαρμακευτικά αποδεκτού άλατος ή επιδιαλυτώματος αυτής, σε ανθρώπους ασθενείς, συμπεριλαμβανομένου ενός συγκεκριμένου πληθυσμού ασθενών. Συγκεκριμένα, παρέχονται εδώ δοσολογία, χρονοδιαγράμματα δοσολογίας ή σχήματα δοσολογίας. Παρέχονται επίσης μέθοδοι θεραπείας πολλαπλασιαστικών ασθενειών ή ασθενειών που οφείλονται σε FLT-3 σε ανθρώπους.
CY20201100138T 2009-05-14 2020-02-14 Ξηρανθεισα με ψεκασμο συνθεση αc220 CY1122765T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17847209P 2009-05-14 2009-05-14
US24397709P 2009-09-18 2009-09-18
PCT/US2010/034926 WO2010132787A1 (en) 2009-05-14 2010-05-14 Methods of treating proliferative diseases

Publications (1)

Publication Number Publication Date
CY1122765T1 true CY1122765T1 (el) 2021-03-12

Family

ID=42289326

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100138T CY1122765T1 (el) 2009-05-14 2020-02-14 Ξηρανθεισα με ψεκασμο συνθεση αc220

Country Status (17)

Country Link
US (2) US8865710B2 (el)
EP (1) EP2429524B1 (el)
AU (2) AU2010248860B2 (el)
CA (1) CA2761940C (el)
CY (1) CY1122765T1 (el)
DK (1) DK2429524T3 (el)
ES (1) ES2773315T3 (el)
FI (1) FIC20240009I1 (el)
HR (1) HRP20200255T1 (el)
HU (2) HUE048309T2 (el)
LT (1) LT2429524T (el)
NO (1) NO2024011I1 (el)
NZ (1) NZ596739A (el)
PL (1) PL2429524T3 (el)
PT (1) PT2429524T (el)
SI (1) SI2429524T1 (el)
WO (1) WO2010132787A1 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2001892T3 (pl) * 2006-03-17 2013-09-30 Ambit Biosciences Corp Imidazolotiazolowe związki do leczenia chorób proliferacyjnych
CA2755976C (en) 2009-03-23 2020-04-07 Ambit Biosciences Corporation Methods of treatment using combination therapy
JP6116847B2 (ja) 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ シクロデキストリンとの混合体を含有する錠剤
WO2015043492A1 (en) * 2013-09-26 2015-04-02 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and uses thereof in medicine
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
CR20170086A (es) 2014-09-09 2017-05-22 Janssen Biotech Inc Terapias de combinación con anticuerpos anti-cd38
PE20171094A1 (es) * 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
CA2976752C (en) 2015-02-20 2019-12-17 Daiichi Sankyo Company, Limited Method for treating cancer by combined use
WO2016187546A1 (en) 2015-05-20 2016-11-24 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
JP6816038B2 (ja) 2015-06-22 2021-01-20 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体及びサバイビン阻害剤による血液悪性疾患の併用療法
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
MY202415A (en) 2015-11-03 2024-04-27 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
PL2001892T3 (pl) 2006-03-17 2013-09-30 Ambit Biosciences Corp Imidazolotiazolowe związki do leczenia chorób proliferacyjnych
TWI437988B (zh) 2007-09-19 2014-05-21 Ambit Biosciences Corp 包含Ｎ－（５－第三丁基－異噁唑－３－基）－Ｎ’－｛４－〔７－（２－嗎啉－４－基－乙氧基）咪唑并〔２，１－ｂ〕〔１，３〕苯并噻唑－２－基〕苯基｝脲之固體形式物、其組合物及與其有關之用途
ES2436266T3 (es) * 2007-11-08 2013-12-30 Ambit Biosciences Corporation Métodos para administrar N-(5-terc-butil-isoxazol-3-il)-N'-{4-[7-(2-morfolin-4-il-etoxi)imidazo[2,1-b][1,3]benzotiazol-2-il]fenil}urea para tratar enfermedades proliferativas
US8551963B2 (en) * 2008-11-06 2013-10-08 Ambit Biosciences Corporation Imidazolothiazole compounds and methods of use thereof
CA2755976C (en) * 2009-03-23 2020-04-07 Ambit Biosciences Corporation Methods of treatment using combination therapy
CA2778940C (en) 2009-11-05 2018-10-16 Ambit Biosciences Corp. Process for the preparation of imidazo[2,1-b][1,3]benzothiazole derivatives
JP6116847B2 (ja) * 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ シクロデキストリンとの混合体を含有する錠剤

Also Published As

Publication number Publication date
EP2429524A1 (en) 2012-03-21
CA2761940C (en) 2018-04-10
FIC20240009I1 (fi) 2024-03-27
NZ596739A (en) 2014-01-31
ES2773315T3 (es) 2020-07-10
HRP20200255T1 (hr) 2020-09-04
US9555040B2 (en) 2017-01-31
PT2429524T (pt) 2020-03-02
EP2429524B1 (en) 2020-01-15
US20160051557A1 (en) 2016-02-25
WO2010132787A1 (en) 2010-11-18
US8865710B2 (en) 2014-10-21
AU2015230806A1 (en) 2015-10-15
LT2429524T (lt) 2020-05-11
HUE048309T2 (hu) 2020-07-28
AU2010248860B2 (en) 2015-06-25
US20120258081A1 (en) 2012-10-11
DK2429524T3 (da) 2020-02-24
NO2024011I1 (no) 2024-03-14
PL2429524T3 (pl) 2020-08-24
AU2010248860A1 (en) 2011-12-22
SI2429524T1 (sl) 2020-07-31
HUS2400008I1 (hu) 2024-04-28
CA2761940A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
CY1122765T1 (el) Ξηρανθεισα με ψεκασμο συνθεση αc220
MX2010002396A (es) Metodos para administrar n-(5-ter-butil-isoxazol-3-il)-n?-{4-[7-(2 -morfolin-4-il-etoxi)imidazo[2, 1-b][1,3]benzotiazol-2-il] fenil} urea para tratar enfermedaes proliferativas.
CY1122466T1 (el) Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
CY1122349T1 (el) Παραγωγα 1-benzyλ-3-υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των mcp-1, cxcr1 και ρ40
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
MX344308B (es) Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso.
EP1592665A4 (en) HISTONE DEACETYLASE INHIBITORS OF NEW POWERFUL DIFFERENTIATION BENZAMIDE DERIVATIVES WITH PROLIFERATION-INHIBITING ACTIVITY
ES2328819T3 (es) Hidroxamatos como agentes terapeuticos.
BRPI0413427A (pt) derivados de piridilpirrol ativos como inibidores da cinase
NL300917I1 (nl) Midostaurine, desgewenst in de vorm van een zout
PA8748101A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
UY28922A1 (es) Ligandos del receptor cb1 útiles en el tratamiento de dolor y/u otros síntomas o enfermedades relacionadas; compuestos farmacéuticos y su preparación.
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
FI3157527T3 (fi) Ezh2-inhibiittoreita lymfoman hoitoon
SV2011003939A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
EA200800538A1 (ru) Терапевтические соединения
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
ATE453646T1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
EA200870360A1 (ru) Бензимидазолы, обладающие активностью в отношении рецепторов м1, и их применение в медицине
CY1108421T1 (el) Η χρηση σκευασματων μελοξικαμης στην κτηνιατρικη
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
EA200971053A1 (ru) Способы лечения кожных язв
EA201270144A1 (ru) Комбинированная терапия при лечении диабета